ToxMap is indispensible at the early stages of preclinical drug development because of the impact of using the human liver as a target organ for the determination of toxicity. This new paradigm will improve the success rate of drug candidates entering development, and provide for a better informed decision in determining which candidate drugs should move forward to the later stages of the development. A decision which now can be taken early in the discovery process and long before the expensive clinical trials. Another very valuable advantage of the ToxMap Technology is the ability to generate and protect IP for the drug candidates at a very early stage in the drug development process by analyzing the effect of the drug on the specific target cells. WELCOME TO TOXICELL